Vineeta Agarwala, general partner at A16Z's Bio & Health fund, on investing in AI for drug discovery.

David Liu, professor of chemistry at Harvard University and co-founder of multiple biotech companies, including Beam Therapeutics and Prime Medicine.

Valerie Daggett, founder and CEO of Seattle-based AltPep, on early detection and treatment of Alzheimer's.

Robert Ang, CEO of Cambridge, Mass.-based Vor Bio, on using CRISPR gene editing to alter bone marrow transplants and improve treatment of acute myeloid leukemia.

Rick Young, professor at MIT and co-founder of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics, on studying gene expression for drug discovery.

Jens Eckstein, investment partner at Hevolution Foundation, on investing in healthy aging.

Shelley Force Aldred and Nathan Trinklein, co-founders of Rondo Therapeutics, on the opportunity with bispecific antibodies for cancer.

Jeff Jonker, CEO of San Diego-based Belharra Therapeutics, on the renaissance in small molecule drug discovery.

Nancy Stagliano, CEO of South San Francisco-based Neuron23, on bringing precision medicine to neuroscience drug discovery.

Diana Brainard, CEO of AlloVir, on leading the fight against infectious diseases.

Reid Huber, partner at Third Rock Ventures, on investing in the future of medicine.

Jeff Huber, co-founder and general partner at Triatomic Capital, on his career path in tech, and then biotech.

Lori Lyons-Williams, CEO of Abdera Therapeutics, on developing targeted radiopharmaceuticals for cancer.

Turning the Tables, Rob Perez Interviews Me

Zach Weinberg and Alexis Borisy of Curie.Bio on Freeing the Biotech Founders

Fred Appelbaum, a physician, scientist and leader at the Fred Hutchinson Cancer Center, on 'Living Medicine,' his new book about the development of bone marrow transplantation and the rise of cell therapy.

Colin Hill, co-founder and CEO of Aitia, on digging deep into biological datasets and finding new drug targets.

Yung Lie, president and CEO of Damon Runyon Cancer Research Foundation, on advancing cancer research by supporting young scientists with bold and brave ideas.

Kevin Conroy, CEO of Exact Sciences, on early detection of cancer.

Jodie Morrison, acting CEO of Q32Bio, on becoming a biotech CEO.

Aaron Ring, a scientist at Yale moving to the Fred Hutchinson Cancer Center, on applying immunology and protein engineering for cancer therapy and more.

Deborah Palestrant, partner at 5AM Ventures and head of the 4:59 initiative, on building biotech startups.

John Maraganore, former founding CEO of Alnylam Pharmaceuticals, on his life in biotech and developing RNA interference as a new class of medicine.

Emile Nuwaysir, CEO of Boston-based Ensoma, on developing off-the-shelf in vivo gene editing therapies.